Conditions: Lung Cancer Carcinoma, Non-Small-Cell Lung
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 13
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess how well this particular combination of chemotherapy, radiation and surgery works to help people with locally advanced lung cancer, how well PET scans indicates whether someone has responded to chemotherapy and radiation, and gene expression patterns related to outcomes in patients with locally advanced lung cancer who receive this treatment regimen.

Detailed description:

Arms:
arm 1: 1. Concurrent weekly docetaxel at 20 mg/m2 and weekly carboplatin at an AUC of 2 with thoracic radiotherapy of 180-200cGy/day for 5/7 days to 45 Gy.
2. Complete surgical excision 3-6 weeks after completion of chemoradiotherapy.
3. No Surgery if patient is deemed unable to tolerate surgery, with completion to 61 Gy radiation
4. Consolidation after surgery: Docetaxel given at 75 mg/m2 every 3 weeks with carboplatin at AUC 6 every 3 weeks with concomitant growth factor support.

Interventions: intervention 1: Docetaxel intervention 2: Carboplatin intervention 3: Radiation therapy intervention 4: Surgical resection
Intervention descriptions: intervention 1: 20 mg/m2, 75 mg/m2 infusion intervention 2: AUC of 2 and 6 infusion intervention 3: NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period. intervention 4: All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.

Protocol document: